American trypanosomiasis and associated risk factors in owned dogs from the major city of Yucatan, Mexico

Jiménez‐Coello, Matilde; Acosta-Viana, Karla Y.; Guzmán-Marín, Eugenia; Bárcenas-Irabién, Alejandra; Ortega‐Pacheco, Antonio

doi:10.1186/s40409-015-0039-2

Cited by 11 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cruz-Chan et al reported the presence of a possible coinfection, having detected antibodies of T. cruzi and D. immitis helminths, and these potentially coinfected animals had lower antibody values (IgM) [ 34 ]. Jiménez-Coello et al detected a seroprevalence in Canis familiaris of 12.2% (45/370), and animals older than two years had a greater risk ( P > 0.06) of becoming infected with T. cruzi than younger animals [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

Historical Spatial Distribution of Zoonotic Diseases in Domestic, Synanthropic, and Wild Animals in the Mexican Territory of the Yucatan Peninsula

Haro

Trasviña-Muñoz

May-Concha

et al. 2021

Journal of Tropical Medicine

View full text Add to dashboard Cite

The Mexican territory of the Yucatan Peninsula has a tropical climate and harbors a wide variety of domestic, synanthropic, and wild animals, as well as disease vectors. To determine the distribution of recorded zoonotic diseases in the Yucatan Peninsula, scientific publications referring to these diseases in animals and containing geographic coordinates of disease occurrence, were studied. The epidemiological bulletins of the national government were also consulted to obtain information on zoonotic diseases reported in humans in the territory. The territory harbors a wide variety of tropical zoonotic pathogens, including Trypanosoma cruzi, Leptospira interrogans, Toxoplasma gondii, Leishmania mexicana, Dirofilaria immitis, and Rickettsia felis. A variety of domestic, synanthropic, and wild animals act as hosts or reservoirs in the transmission cycle of the zoonotic diseases in the Yucatan Peninsula, and some spillover into human populations has also been recorded. There are still zoonotic diseases that have rarely or never been reported in humans, but it is not clear whether this is because these diseases in humans are not common, there is a lack of viable transmission cycle or there is a lack of appropriate diagnosis. It is necessary to continue monitoring vectors, animal hosts, and humans to identify risk factors for zoonotic diseases in the Yucatan Peninsula.

show abstract

Section: Resultsmentioning

confidence: 99%

Historical Spatial Distribution of Zoonotic Diseases in Domestic, Synanthropic, and Wild Animals in the Mexican Territory of the Yucatan Peninsula

Haro

Trasviña-Muñoz

May-Concha

et al. 2021

Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…cruzi prevalence value of 32.5% in T . dimidiata [ 17 – 25 ], and seroprevalence estimates of 1.85% in humans[ 25 – 35 ], and 14.58% in dogs[ 17 , 28 , 29 , 36 – 39 ]. We assumed the impact of treatment in the chronic stage was negligible as it has limited effectiveness and takes years for sero-reversion to occur.…”

Section: Methodsmentioning

confidence: 99%

The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission

Bartsch¹,

Avelis²,

Asti³

et al. 2018

PLoS Negl Trop Dis

View full text Add to dashboard Cite

BackgroundThe World Health Organization’s 2020 Goals for Chagas disease include access to antiparasitic treatment and care of all infected/ill patients. Policy makers need to know the economic value of identifying and treating patients earlier. However, the economic value of earlier treatment to cure and prevent the Chagas’ spread remains unknown.MethodsWe expanded our existing Chagas disease transmission model to include identification and treatment of Chagas disease patients. We linked this to a clinical and economic model that translated chronic Chagas disease cases into health and economic outcomes. We evaluated the impact and economic outcomes (costs, cost-effectiveness, cost-benefit) of identifying and treating different percentages of patients in the acute and indeterminate disease states in a 2,000-person village in Yucatan, Mexico.ResultsIn the absence of early treatment, 50 acute and 22 new chronic cases occurred over 50 years. Identifying and treating patients in the acute stage averted 0.5–5.4 acute cases, 0.6–5.5 chronic cases, and 0.6–10.8 disability-adjusted life years (DALYs), saving $694-$7,419 and $6,976-$79,950 from the third-party payer and societal perspectives, respectively. Treating in the indeterminate stage averted 2.2–4.9 acute cases, 6.1–12.8 chronic cases, and 11.7–31.1 DALYs, saving $7,666-$21,938 from the third-party payer perspective and $90,530-$243,068 from the societal perspective. Treating patients in both stages averted ≤9 acute cases and ≤15 chronic cases. Identifying and treating patients early was always economically dominant compared to no treatment. Identifying and treating patients earlier resulted in a cumulative cost-benefit of $7,273-$224,981 at the current cost of identification and treatment.ConclusionsEven when identifying and treating as little as 5% of cases annually, treating Chagas cases in the acute and indeterminate stages reduces transmission and provides economic and health benefits. This supports the need for improved diagnostics and access to safe and effective treatment.

show abstract

“…cruzi prevalence value of 32.5% in T . dimidiata [ 27 , 31 – 38 ], and seroprevalence estimates of 1.85% in humans[ 4 , 38 – 47 ], and 14.58% in dogs[ 31 , 41 , 42 , 48 – 51 ]. As transmission probabilities (i.e., from vectors to humans and dogs, and from dogs and humans to triatomines) and T .…”

Section: Methodsmentioning

confidence: 99%

Are the London Declaration’s 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula

et al. 2018

View full text Add to dashboard Cite

BackgroundThe 2020 Sustainable Development goals call for 100% certified interruption or control of the three main forms of Chagas disease transmission in Latin America. However, how much will achieving these goals to varying degrees control Chagas disease; what is the potential impact of missing these goals and if they are achieved, what may be left?MethodsWe developed a compartmental simulation model that represents the triatomine, human host, and non-human host populations and vector-borne, congenital, and transfusional T. cruzi transmission between them in the domestic and peridomestic settings to evaluate the impact of limiting transmission in a 2,000 person virtual village in Yucatan, Mexico.ResultsInterruption of domestic vectorial transmission had the largest impact on T. cruzi transmission and prevalence in all populations. Most of the gains were achieved within the first few years. Controlling vectorial transmission resulted in a 46.1–83.0% relative reduction in the number of new acute Chagas cases for a 50–100% interruption in domestic vector-host contact. Only controlling congenital transmission led to a 2.4–8.1% (30–100% interruption) relative reduction in the total number of new acute cases and reducing only transfusional transmission led to a 0.1–0.3% (30–100% reduction). Stopping all three forms of transmission resulted in 0.5 total transmission events over five years (compared to 5.0 with no interruption); interrupting all forms by 30% resulted in 3.4 events over five years per 2,000 persons.ConclusionsWhile reducing domestic vectorial, congenital, and transfusional transmission can successfully reduce transmission to humans (up to 82% in one year), achieving the 2020 goals would still result in 0.5 new acute cases per 2,000 over five years. Even if the goals are missed, major gains can be achieved within the first few years. Interrupting transmission should be combined with other efforts such as a vaccine or improved access to care, especially for the population of already infected individuals.

show abstract

American trypanosomiasis and associated risk factors in owned dogs from the major city of Yucatan, Mexico

Cited by 11 publications

References 22 publications

Historical Spatial Distribution of Zoonotic Diseases in Domestic, Synanthropic, and Wild Animals in the Mexican Territory of the Yucatan Peninsula

Historical Spatial Distribution of Zoonotic Diseases in Domestic, Synanthropic, and Wild Animals in the Mexican Territory of the Yucatan Peninsula

The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission

Are the London Declaration’s 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula

Contact Info

Product

Resources

About